Company Quick10K Filing
Acro Biomedical
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 48 $177
10-K 2020-01-07 Annual: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
10-Q 2019-05-15 Quarter: 2019-03-31
10-Q 2019-02-14 Quarter: 2018-12-31
10-K 2018-12-28 Annual: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-08-01 Quarter: 2018-03-31
S-1 2018-02-15 Public Filing
10-Q 2018-02-14 Quarter: 2017-12-31
10-K 2018-01-16 Annual: 2017-09-30
10-Q 2017-08-11 Quarter: 2017-06-30
10-Q 2017-05-22 Quarter: 2017-03-31
10-Q 2017-02-14 Quarter: 2016-12-31
10-K 2016-12-16 Annual: 2016-09-30
10-Q 2016-08-03 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
8-K 2020-01-13 Amend Bylaw
8-K 2018-10-18 Accountant, Exhibits
8-K 2018-07-06 Accountant
8-K 2018-06-19 Accountant, Exhibits

Acro Biomedical Financials

ACBM Metrics, Comps, Filings

Annual | Quarterly

Business

We have been engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle since 2017. Our initial business plan was to build a family waterpark in a state-of-the-art designed aquatic center in several locations throughout the Hawaiian Islands. We were not able to develop this business and we did not generate any revenues in this business. Following a change of control on January 30, 2017, resulting from the sale by the then principal stockholder of 36,000,000 shares of common stock, constituting all of his stock and 76.3% of the then outstanding common stock, we discontinued our efforts to develop aquatic centers. Our business to date has involved purchase products from two suppliers and selling these products to two unrelated customers.

Our first sale was made in September 2017. All of our sales to date have been sales of cordyceps related products and, commencing in the second quarter of the year ended September 30, 2018, metallothionein MT-3 elizer. We may also seek to market other products which we see as complimentary to our present products.

Cordyceps is a fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. It is a rare combination of a caterpillar and a fungus and found at altitudes above 4500m in Sikkim. According to the Journal of Ayuveda and Integrative Medicine, the fungus is parasitic in nature. The base of the mushroom first originates from an insect larval host and ends at the club-like cap, including the stipe and stroma. The fruit body is dark brown to black, and the root of organism, the larval body pervaded by the mycelium, is yellowish to brown color. The immature larvae (host) on which cordyceps grows usually lies about 6 inches below the surface of the ground. As the fungus approaches maturity, it consumes more than 90% of the infected insect effectively mummifying its host. Local folk practitioners use the product alone or in combination with other medicinal herbs to treat various diseases. However, the effectiveness of Cordyceps sinensis, either alone or with other medicinal herbs, has not been shown as effective in double blind tests, and it has not been subject to the type of testing that would be required for prescription medication. As a result, in the United States we cannot make any claims as to specific health benefits.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Cure Pharmaceutical (CURR) 189,733 69% -8.3 -82% 35,347 25,254 504 350 -28,813 -22,134 182,638
Health Catalyst (HCAT) 187,144 0% -21.3 -8% 139,676 112,251 36,804 0 -10,694 -8,467 180,703
Bicycle Therapeutics (BCYC) 184,557 0% -7.5 -8% 126,246 21,687 1,522 0 -10,217 -10,082 76,021
Technovative Group (TEHG) 182,172 57% -105.6 -33% 5,191 3,101 765 437 -1,719 -1,719 181,597
Acro Biomedical (ACBM) 177,190 10% -1,443.4 -13% 1,081 133 2,916 284 -142 -123 177,189
Energy & Technology (ENGT) 177,150 32% -1,446.0 -4% 3,954 9,029 3,101 984 -143 -122 177,039
Emergent Capital (EMG) 177,018 0% -5.2 -69% 85,384 121,307 35,301 0 -58,692 -33,490 175,594
Fingermotion (FNGR) 174,552 18% -49.3 -72% 5,040 4,082 2,223 394 -3,618 -3,538 174,401
Pacific Green Technologies (PGTK) 172,614 31% -8.1 -49% 44,312 43,736 6,839 2,086 -21,904 -21,013 169,834
Cytodyn (CYDY) 171,286 -3.5 -269% 20,874 29,788 0 0 -56,187 -48,802 172,474
Franklin Financial Services (FRAF) 170,440 3.6 1% 1,252,141 1,128,227 0 0 15,025 24,601 87,992
Stereotaxis (STXS) 169,349 80% -40.1 -20% 21,255 16,597 28,632 23,009 -4,237 -4,012 160,877
HOOKIPA Pharma (HOOK) 168,392 0% -1.6 -13% 168,095 32,062 6,286 0 -21,408 -20,885 33,179
United Health Products (UEEC) 167,759 -145% -33.7 -754% 637 694 39 -57 -4,800 -4,957 167,259
Vaneck Merk Gold Trust (OUNZ) 167,233 7.3 14% 160,696 0 0 0 23,066 23,066 167,233
New York REIT (NYRT) 167,183 0% -22.7 12,387,300,000% 168,406 0 -123,873 -5,348 121,647
DOCASA (DCSA) 166,631 9% -80.6 -12% 22,047 6,626 16,112 1,527 -2,682 -2,057 165,842
Jamba (JMBA) 165,009 0% 68.1 -4% 36,654 46,912 78,265 0 -1,563 2,289 155,914
QNB (QNBC) 161,973 5.8 1% 1,212,005 1,096,127 0 0 12,060 25,667 147,905
Diverse Development Group (DDG) 161,311 -2,021.4 -401,195% 0 163 0 0 -80 -80 161,311

Balance Sheet ($'000)2016-09-302017-12-312018-09-30
Cash391
Accounts Receivable
Inventory7161,147
PP&E
Assets37651,483
Accounts Payable
Long-Term Debt
Liabilities17173241
Stockholders' Equity-155921,242
Income Statement ($'000)2016-09-302017-12-312018-09-30
Revenue08,014
Cost of Revenue7,181
Gross Profit833
R&D
SG&A1318
Tax092
Net Income-43420
Cash Flow ($'000)2016-09-302017-12-312018-09-30
Cash Operating-35-140
Cash Investing
Cash Financing10105